Replies to post #177070 on Xechem International Inc. (fka XKEM)

[TheRaveninexile]

There was no point in persuing generic paclataxel because the market has been flooded by cheap chinese supply. This was a prudent move by the company. On another front though there seems to be a lot of evidence that Xechem is actively engaged in NIPRD's project to produce domestic artemsia based anti-malarials. Without the plant extraction processes developed by Xechem and instituted by NIPRD they wouldn't be as far along as they are.

[Eli's Gone]

and I find the very next paragraph after your quote interesting as well...

Meanwhile, Xechem is seeking approval to market the sickle cell treatment in the United States and Europe. “A company that is centered on a niche drug isn’t necessarily a bad thing,” says Andersen. “They might be able to charge thousands of dollars for treatment if the drug is approved in the U.S. or Europe.”